-
公开(公告)号：US20170312351A1
公开(公告)日：2017-11-02
申请号：US15468046
申请日：2017-03-23
IPC分类号： A61K39/00 , C12N7/00 , C12N15/86 , G06F19/18 , A61K39/39 , C07K14/74 , C07K14/705 , C07K7/06
CPC分类号： A61K39/0011 , A61K39/39 , A61K2039/5254 , A61K2039/5256 , A61K2039/57 , A61K2039/572 , A61K2039/70 , C07K7/06 , C07K14/70539 , C07K14/70596 , C07K2319/01 , C07K2319/06 , C07K2319/40 , C07K2319/95 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10334 , C12N2710/10343 , C12N2840/002 , G16B20/00
摘要： Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
-
公开(公告)号：US09463184B2
公开(公告)日：2016-10-11
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A01N43/76 , A61K31/42 , A01N43/08 , A61K31/34 , A01N43/20 , A01N43/24 , A61K31/335 , A61K31/423 , A61K31/05 , A61K31/12 , A61K31/365 , A61K31/404 , A61K31/407 , A61K33/24 , A61K9/00 , A61K47/06 , A61K47/10 , A61K31/341 , A61K31/16 , A61K31/66
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
33.发明授权公开(公告)号：US09315464B1
公开(公告)日：2016-04-19
申请号：US14170353
申请日：2014-01-31
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： C07D215/52 , C07D401/12 , C07D401/04 , C07D405/14 , C07D413/12 , C07D413/14 , C07D401/14 , G06F19/12 , C07D498/04 , C07D417/12 , C07D417/14
CPC分类号： C07D215/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04 , G06F19/12
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
摘要翻译： 考虑到对RNA病毒，特别是正粘病毒具有显着抗病毒作用的组合物，化合物和方法，并靶向由病毒基因组的5'和3'-UTR序列形成的病毒启动子。
-
公开(公告)号：US12072337B2
公开(公告)日：2024-08-27
申请号：US16615360
申请日：2018-05-21
IPC分类号： G01N33/574 , A61K35/17 , C07K16/30
CPC分类号： G01N33/57492 , A61K35/17 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/565
摘要： Systems and methods for validating immune therapy that targets patient- and tumor-specific neoepitopes are presented in which cellular components are identified and/or used that present patient- and tumor-specific neoepitopes. Presence of these neoepitopes confirms the suitability of the neoepitopes. Advantageously, synthetic antibodies are created based on in silico analysis of the tumor genome and RNA or phage display, and can be used to isolate cellular components, and especially circulating tumor cells, metastatic cells, and/or exosomes and microvesicles.
-
公开(公告)号：US11441160B2
公开(公告)日：2022-09-13
申请号：US16836515
申请日：2020-03-31
IPC分类号： A61K38/19 , A61K38/20 , A61K35/761 , A61K39/00 , C12N15/86
摘要： Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.
-
公开(公告)号：US11229668B2
公开(公告)日：2022-01-25
申请号：US16483978
申请日：2018-02-08
发明人： Shahrooz Rabizadeh , Kayvan Niazi , Patrick Soon-Shiong , Hing Wong , Wenxin Xu
IPC分类号： A61K35/17 , A61K31/675 , C07K14/52 , C12N15/86
摘要： Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and/or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and/or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.
-
公开(公告)号：US10322177B2
公开(公告)日：2019-06-18
申请号：US15288910
申请日：2016-10-07
发明人： Ting Wu , Kayvan Niazi
IPC分类号： A61K41/00 , A61K31/708 , A61K38/05
摘要： Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell. Notably, cells can be transfected in very large quantities at high viability, with the transfected cells exhibiting up-regulated immune responses.
-
公开(公告)号：US20170128450A1
公开(公告)日：2017-05-11
申请号：US15213049
申请日：2016-07-18
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure LeNy , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , C07D487/04
摘要： Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
-
公开(公告)号：US20170100479A1
公开(公告)日：2017-04-13
申请号：US15288910
申请日：2016-10-07
发明人： Ting Wu , Kayvan Niazi
IPC分类号： A61K41/00 , A61K38/05 , A61K31/708
CPC分类号： A61K41/00 , A61K31/708 , A61K38/05 , A61K41/0028
摘要： Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell. Notably, cells can be transfected in very large quantities at high viability, with the transfected cells exhibiting up-regulated immune responses.
-
公开(公告)号：US20150297572A1
公开(公告)日：2015-10-22
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A61K31/423 , A61K31/365 , A61K9/00 , A61K31/341
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.029 秒)
